Bladder Cancer - Results from #440

The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. July 18, 2024

Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. July 18, 2024

Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. July 17, 2024

NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors. July 17, 2024

Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer. July 17, 2024

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization July 16, 2024

Bladder Cancer Advocacy Network (BCAN) Announces $600,000 in Funding to Propel Breakthroughs in Bladder Cancer Research July 16, 2024

Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy. July 16, 2024

Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer. July 16, 2024

PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety. July 15, 2024

Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. July 15, 2024

Potential of an mRNA-Based Urine Assay (Xpert® Bladder Cancer Detection1) in Hematuria Patients - Results from a Cohort Study. July 15, 2024

Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review. July 15, 2024

Clinical, Pathological Characteristics and Progression of Urothelial Bladder Cancer in Young Adult Patients. Our Experience and Literature Review. July 12, 2024

Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence. July 12, 2024

Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France. July 11, 2024

Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. July 11, 2024

Bladder Epicheck® for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience and follow-up proposal. July 11, 2024

DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group. July 11, 2024

Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma with Prognostic Implications. July 10, 2024

Page 23 of 528